Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study

Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study

Hideaki Katagiri,1 Masanori Taketsuna,2 Shinpei Kondo,3 Kenta Kajimoto,4 Etsuko Aoi,5 Yuka Tanji1 1Bio Medicine, 2Statistical Sciences, 3Post Marketing Study Management, 4Scientific Communications, Medicines Development Unit Japan, 5Global Patient Safety Japan, Quality and Patient Safety, Eli Lilly...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Katagiri H, Taketsuna M, Kondo S, Kajimoto K, Aoi E, Tanji Y
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
Agitation
Japanese
Postmarketing Surveillance Study
Rapid-Acting Intramuscular Olanzapine
Schizophrenia
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Acceso en línea:https://doaj.org/article/1f759ce9f6f440dd9576b46920cb5df4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/1f759ce9f6f440dd9576b46920cb5df4

Ejemplares similares